EMEA-002640-PIP01-19
Key facts
| Active substance |
Cendakimab
|
| Therapeutic area |
Gastroentology-Hepatology
|
| Decision number |
P/0375/2021
|
| PIP number |
EMEA-002640-PIP01-19
|
| Pharmaceutical form(s) |
Solution for injection
|
| Condition(s) / indication(s) |
Treatment of eosinophilic esophagitis
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
Bristol-Myers Squibb Pharma EEIG
E-mail: medical.information@bms.com |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|